Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Audenz Phase 3 in Healthy Adults
NCT02839330Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Jul 2016
- Primary completion
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of MF59-eH5N1 in Avian Influenza (AI), sponsored by CSL Seqirus. Started Jul 2016; status: completed.
02
Drugs
MF59-eH5N1
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT02839330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839330.